Literature DB >> 12205027

Persistence of microscopic human cancers in mice: alterations in the angiogenic balance accompanies loss of tumor dormancy.

Taturo Udagawa1, Antonio Fernandez, Eike-Gert Achilles, Judah Folkman, Robert J D'Amato.   

Abstract

Some human tumor lines do not form visible tumors when inoculated into immunosuppressed mice. The fate of these human tumor lines was followed by transfecting them with green fluorescence protein before inoculating them into mice. Although the tumor lines failed to grow progressively, they formed small dormant microscopic foci maintained at constant mass by balanced proliferation and apoptosis. Transfecting the cells with either VEGF165 or activated c-Ha-ras induced loss of dormancy, which correlated with a shift in the angiogenic balance toward increased vascularity with reduced tumor cell apoptosis. These results support a model in which loss of dormancy is controlled in part by a switch to an angiogenic phenotype. These tumor lines may serve as models for investigating the cellular mechanisms controlling dormancy and identifying those factors that promote the loss of balanced proliferation and apoptosis. Finally, these models may prove useful in the design and testing of therapies directed toward eradicating dormant tumors and preventing tumor recurrence.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12205027     DOI: 10.1096/fj.01-0813com

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  23 in total

1.  Expression profiling of angiogenesis-related genes in brain metastases of lung cancer and melanoma.

Authors:  Aysegül Ilhan-Mutlu; Christian Siehs; Anna Sophie Berghoff; Gerda Ricken; Georg Widhalm; Ludwig Wagner; Matthias Preusser
Journal:  Tumour Biol       Date:  2015-08-16

Review 2.  Purinergic mechanisms in breast cancer support intravasation, extravasation and angiogenesis.

Authors:  Iain L O Buxton; Nucharee Yokdang; Robert M Matz
Journal:  Cancer Lett       Date:  2010-05-28       Impact factor: 8.679

3.  Oncologic Angiogenesis Imaging in the clinic---how and why.

Authors:  Karen A Kurdziel; Liza Lindenberg; Peter L Choyke
Journal:  Imaging Med       Date:  2011-09

4.  Tumor dormancy due to failure of angiogenesis: role of the microenvironment.

Authors:  George N Naumov; Judah Folkman; Oddbjorn Straume
Journal:  Clin Exp Metastasis       Date:  2008-06-18       Impact factor: 5.150

Review 5.  Hypoxia in microscopic tumors.

Authors:  Xiao-Feng Li; Joseph A O'Donoghue
Journal:  Cancer Lett       Date:  2008-04-01       Impact factor: 8.679

6.  Spontaneous reversion of the angiogenic phenotype to a nonangiogenic and dormant state in human tumors.

Authors:  Michael S Rogers; Katherine Novak; David Zurakowski; Lorna M Cryan; Anna Blois; Eugene Lifshits; Trond H Bø; Anne M Oyan; Elise R Bender; Michael Lampa; Soo-Young Kang; Kamila Naxerova; Karl-Henning Kalland; Oddbjorn Straume; Lars A Akslen; Randolph S Watnick; Judah Folkman; George N Naumov
Journal:  Mol Cancer Res       Date:  2014-02-26       Impact factor: 5.852

7.  Thrombospondin-1 repression is mediated via distinct mechanisms in fibroblasts and epithelial cells.

Authors:  R S Watnick; R K Rodriguez; S Wang; A L Blois; A Rangarajan; T Ince; R A Weinberg
Journal:  Oncogene       Date:  2014-08-11       Impact factor: 9.867

8.  Progression of ocular melanoma metastasis to the liver: the 2012 Zimmerman lecture.

Authors:  Hans E Grossniklaus
Journal:  JAMA Ophthalmol       Date:  2013-04       Impact factor: 7.389

9.  New concepts in breast cancer emerge from analyzing clinical data using numerical algorithms.

Authors:  Michael Retsky
Journal:  Int J Environ Res Public Health       Date:  2009-01-20       Impact factor: 3.390

10.  Design and modification of EGF4KDEL 7Mut, a novel bispecific ligand-directed toxin, with decreased immunogenicity and potent anti-mesothelioma activity.

Authors:  B J Stish; S Oh; H Chen; A Z Dudek; R A Kratzke; D A Vallera
Journal:  Br J Cancer       Date:  2009-10-06       Impact factor: 9.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.